Comparison of intradermal dilutional testing with the multi-test II applicator in testing for mold allergy

Jacques Peltier; Matthew W. Ryan

doi:10.1016/j.otohns.2005.10.051

Comparison of intradermal dilutional testing with the multi-test II applicator in testing for mold allergy

Jacques Peltier, Matthew W. Ryan

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

OBJECTIVES: To compare and correlate wheal size using the Multi-Test II applicator with the endpoint obtained by intradermal dilutional testing (IDT) for common mold allergens. To validate the safety and efficacy of modified quantitative testing (MQT) for determining immunotherapy starting doses. STUDY DESIGN AND SETTING: Prospective study of 86 subjects with Multi-Test II and IDT for 6 common mold antigens. RESULTS: There was 84% concordance between IDT results and the results expected from the MQT method. When IDT and MQT results differed, the MQT algorithm predicted a safer endpoint for starting immunotherapy in all but 2 cases. CONCLUSION: The correlation between Multi-Test II and IDT is not strong enough to infer IDT endpoint from Multi-Test II results for molds. MQT is nearly as effective as formal IDT in determining endpoint. SIGNIFICANCE: MQT appears to be a safe method for determining starting doses for immunotherapy with fungal allergens. EBM rating: B-3b

Original language	English (US)
Pages (from-to)	240-244
Number of pages	5
Journal	Otolaryngology - Head and Neck Surgery
Volume	134
Issue number	2
DOIs	https://doi.org/10.1016/j.otohns.2005.10.051
State	Published - Feb 2006

ASJC Scopus subject areas

Surgery
Otorhinolaryngology

Access to Document

10.1016/j.otohns.2005.10.051

Cite this

@article{1c70a5573f6047ccbdd36f9762392ba3,

title = "Comparison of intradermal dilutional testing with the multi-test II applicator in testing for mold allergy",

abstract = "OBJECTIVES: To compare and correlate wheal size using the Multi-Test II applicator with the endpoint obtained by intradermal dilutional testing (IDT) for common mold allergens. To validate the safety and efficacy of modified quantitative testing (MQT) for determining immunotherapy starting doses. STUDY DESIGN AND SETTING: Prospective study of 86 subjects with Multi-Test II and IDT for 6 common mold antigens. RESULTS: There was 84% concordance between IDT results and the results expected from the MQT method. When IDT and MQT results differed, the MQT algorithm predicted a safer endpoint for starting immunotherapy in all but 2 cases. CONCLUSION: The correlation between Multi-Test II and IDT is not strong enough to infer IDT endpoint from Multi-Test II results for molds. MQT is nearly as effective as formal IDT in determining endpoint. SIGNIFICANCE: MQT appears to be a safe method for determining starting doses for immunotherapy with fungal allergens. EBM rating: B-3b",

author = "Jacques Peltier and Ryan, {Matthew W.}",

year = "2006",

month = feb,

doi = "10.1016/j.otohns.2005.10.051",

language = "English (US)",

volume = "134",

pages = "240--244",

journal = "Otolaryngology - Head and Neck Surgery",

issn = "0194-5998",

publisher = "Mosby Inc.",

number = "2",

}

TY - JOUR

T1 - Comparison of intradermal dilutional testing with the multi-test II applicator in testing for mold allergy

AU - Peltier, Jacques

AU - Ryan, Matthew W.

PY - 2006/2

Y1 - 2006/2

N2 - OBJECTIVES: To compare and correlate wheal size using the Multi-Test II applicator with the endpoint obtained by intradermal dilutional testing (IDT) for common mold allergens. To validate the safety and efficacy of modified quantitative testing (MQT) for determining immunotherapy starting doses. STUDY DESIGN AND SETTING: Prospective study of 86 subjects with Multi-Test II and IDT for 6 common mold antigens. RESULTS: There was 84% concordance between IDT results and the results expected from the MQT method. When IDT and MQT results differed, the MQT algorithm predicted a safer endpoint for starting immunotherapy in all but 2 cases. CONCLUSION: The correlation between Multi-Test II and IDT is not strong enough to infer IDT endpoint from Multi-Test II results for molds. MQT is nearly as effective as formal IDT in determining endpoint. SIGNIFICANCE: MQT appears to be a safe method for determining starting doses for immunotherapy with fungal allergens. EBM rating: B-3b

AB - OBJECTIVES: To compare and correlate wheal size using the Multi-Test II applicator with the endpoint obtained by intradermal dilutional testing (IDT) for common mold allergens. To validate the safety and efficacy of modified quantitative testing (MQT) for determining immunotherapy starting doses. STUDY DESIGN AND SETTING: Prospective study of 86 subjects with Multi-Test II and IDT for 6 common mold antigens. RESULTS: There was 84% concordance between IDT results and the results expected from the MQT method. When IDT and MQT results differed, the MQT algorithm predicted a safer endpoint for starting immunotherapy in all but 2 cases. CONCLUSION: The correlation between Multi-Test II and IDT is not strong enough to infer IDT endpoint from Multi-Test II results for molds. MQT is nearly as effective as formal IDT in determining endpoint. SIGNIFICANCE: MQT appears to be a safe method for determining starting doses for immunotherapy with fungal allergens. EBM rating: B-3b

UR - http://www.scopus.com/inward/record.url?scp=31944444990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31944444990&partnerID=8YFLogxK

U2 - 10.1016/j.otohns.2005.10.051

DO - 10.1016/j.otohns.2005.10.051

M3 - Article

C2 - 16455371

AN - SCOPUS:31944444990

SN - 0194-5998

VL - 134

SP - 240

EP - 244

JO - Otolaryngology - Head and Neck Surgery

JF - Otolaryngology - Head and Neck Surgery

IS - 2

ER -

Comparison of intradermal dilutional testing with the multi-test II applicator in testing for mold allergy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this